- On January 21, 2022, a United States federal district court entered a preliminary injunction preventing infringement of Lonza’s patents related to its innovative Cocoon® Platform
- Adva Biotechnology Ltd. is enjoined from making, using, selling, offering to sell, and importing into the United States the Adva X3 system pending resolution of the case
Basel, Switzerland, 25 January 2022 – On January 21, 2022, in the United States District Court for the District of Maryland, Lonza, a leading global cell and gene therapy manufacturer, obtained a preliminary injunction against Adva Biotechnology Ltd. (“Adva”) preventing Adva from importing and offering their Adva X3 device in the United States pending resolution of the case.
On October 23, 2020, Lonza brought suit against Adva, alleging Adva’s infringement of Lonza and their affiliate Octane Biotech Inc.’s patents covering the innovative Cocoon® Platform. The Cocoon® Platform is an automated and closed platform for patient-scale cell therapy manufacturing, designed to overcome manufacturing challenges associated with patient-scale personalized medicines. The Cocoon® Platform is commercially available and gaining global traction as the go-to manufacturing platform for patient-scale cell therapies.
According to Lonza’s court filings, Adva’s system—the ADVA X3—infringes Lonza and Octane Biotech Inc.’s patents including U.S. Patent Nos. 10,844,338; 10,723,986; 9,783,768; 9,701,932; 9,534,195; 9,499,780; and 8,492,140. Details of the case can be found at case number 8:20-cv-03099-PX. With this order, Lonza further demonstrates its position as a leading innovator in the cell therapy manufacturing market and will continue to provide its leading solutions to therapy developers and ultimately to patients.
As a leading innovator in the pharmaceutical and biologics manufacturing industry, Lonza has many patents covering their innovative offerings.
For more information on Lonza’s patent portfolio please visit www.lonza.com/ip.